BLUETTI
11.7.2022 13:49:10 CEST | Business Wire | Press release
Do I have to be an Amazon Prime Member to take advantage of BLUETTI Prime Day deals?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220710005073/en/
The short answer: nope. But if you’d like to grab the Prime Day sales only on Amazon , you’ll need to be an Amazon Prime Member.
BLUETTI confirms its annual shopping event - BLUETTI Prime Day date on July 5 - 15. To help you narrow things down, they've collected the best deals on their official website , from solar power stations, solar panels to various accessories worth your money.
The Best Prime Day Deals From BLUETTI
AC200P - The Most Popular 2kWh Solar Generator Now At The Lowest Price Ever - 1.699€ (was 1.999€)
Packed with a 2kW AC pure sine wave inverter, an enormous 2kWh capacity, and utilizing the most durable, safest LiFePO4 battery chemistry, the BLUETTI AC200P is undoubtedly the most cost-effective solar generator .
It can power all your needs from a household fridge to an 8.000 BTU portable air conditioner without breaking a sweat. Recharging by solar at a blistering speed up to 700W. You can juice up AC200P from zero to full in less than 4 hours with free, clean solar power alone!
AC200MAX - All-round Upgraded Power Beast - 2.099€ (was 2.399€)
With two expansion battery ports, the AC200MAX welcomes up to two BLUETTI B230 (2048Wh each) or B300 (3072Wh each) battery modules, allowing you to build on your system up to 8192Wh!
The AC200MAX allows up to 900W solar input and 400W via the AC wall charger, giving you a stunning 1300W total charging input to recharge it in less than 2 hours.
BLUETTI AC300 & B300 - Power Anything Imaginable - 3.899€ (was 4.299€)
Unlike any BLUETTI solar generator products, the AC300 has no built-in battery, bringing it unprecedented mobility and uniqueness. Every AC300 can accept up to 4 B300 (3072Wh each) battery modules, adding up to a groundbreaking 12288Wh capacity – Covering your whole family’s basic needs for DAYS during emergencies or power outages!
Time to plug into full-time solar life! BLUETTI AC300 is now capable of receiving 2400W of unrivaled solar charging input. The advanced MPPT controller lets you juice up a B300 (3072Wh) battery module as soon as 1,5hrs only with sunshine!
Other units highly recommended on BLUETTI UK & EU Prime Day 2022:
EB55 - 537Wh, 700W | Portable Solar Generator
- £549 (was £599);
EB70 - 716Wh, 1000W | Portable Power Station
- £649 (was £739);
B230 - 2048Wh LFP Expansion Battery
- £1399 (was £1499);
EP500Pro - 5100Wh, 3000W | Home Backup Power
- £5399 (was £5999)
AC200MAX & B230 - 4096Wh, 2200W | Portable Solar Generator
- £3199 (was £3499)
EB55 - 537Wh, 700W | Portable Solar Generator
- 599€ (was 649€);
EB70 - 716Wh, 1.000W | Portable Power Station
- 699€ (was 749€);
B230 - 2.048Wh LFP Expansion Battery
- 1.399€ (was 1.599€);
EP500Pro 5.100Wh, 3.000W | Home Backup Power
- 5.399€ (was 5.999€)
AC200MAX & 2/B230 & 3/SP200 - 6.144Wh, 2.200W | Bundles
- 6.394€ (was 8.249€)
About BLUETTI
With over 10 years of industry experience, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for everyone and the world. BLUETTI is making its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom